Skip to main content
SpringerLink
Log in

Adalimumab/Duloxetine/Ustekinumab

Heart failure with reduced ejection fraction secondary to non-ischaemic dilated cardiomyopathy and loss of response

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Morgenweck E, et al. Heart failure associated with ustekinumab therapy for treatment of Crohn's Disease. Drug and Therapeutics Bulletin 61: 1-3, No. 11, Jun 2023. Available from: URL: https://dx.doi.org/10.1136/dtb.2023.250376rep

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/Duloxetine/Ustekinumab. Reactions Weekly 1989, 16 (2024). https://doi.org/10.1007/s40278-024-52162-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-024-52162-z

Search

Navigation